e-Drug3D

1993

EXATECAN

INN
EXATECAN
FAM-TRASTUZUMAB DERUXTECAN-NXKI

cas 171335-80-1

CLASS

ANTINEOPLASTIC
ANTIBODY-DRUG CONJUGATE (ADC)
A TOPOISOMERASE INHIBITOR
TREATMENT OF UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER
INTRACELLULAR LINKER LEAVAGE BY LYSOSOMAL ENZYMES
THE MEMBRANE-PERMEABLE DXD CAUSES DNA DAMAGE

ROUTE (list)

INJECTION IV

ATC code

L01FD04

PK parameters

Cl 19.2 LITER / HOUR
PPB 97 PERCENT
t1/2 139.2 HOUR

Target

TARGET TOPOISOMERASE

DrugCentral

Receptor tyrosine-protein kinase erbB-2 UNIPROT P04626 ERBB2

DNA topoisomerase 1 UNIPROT P11387 TOP1

Download SDF file

10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-

Formula:
C24H22FN3O4

Calculated chemical properties:

MW 435.45
NB_atoms 32
XLogP 2.47
PSA 97.877
NB_HD 3
NB_HA 7
fsp3 0.38
Lipinski(0=no;1=yes) 1

FDA
NDA 761139 (pdf not found) INN (FAM-TRASTUZUMAB DERUXTECAN-NXKI) ENHERTU (DAIICHI SANKYO) APPROVAL= AP YEAR= 2019
NDA 761394 (pdf not found) INN (DATOPOTAMAB DERUXTECAN-DLNK) DATROWAY (DAIICHI SANKYO INC) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY
NDA 761464 (pdf not found) INN (DATOPOTAMAB DERUXTECAN-DLNK) DATROWAY (DAIICHI SANKYO INC) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY